Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
I found Zenopa very helpful while looking for employment. I was sent jobs that might be suitable for me and then contacted to go through them in more detail.
Jennifer, 2013

Dr Reddy's highlights positive trends in Q2 2010 fiscal report

26 October 2010 00:00 in Pharmacy Supplier News


Dr Reddy's has highlighted a number of positive trends underpinning business growth in its financial report for the second quarter of its 2010-11 fiscal year.

The generic pharmaceutical specialist reported a consolidated revenue figure of 18.7 billion rupees (264.7 million pounds), two percent ahead of last year's second quarter figure, while gross profits advanced by 15 percent in the same time frame.

Of this total, 13.7 billion rupees were contributed by its global generics segment, which grew by eight percent year-on-year, thanks to the contributions from branded generics markets.

Dr Reddy's launched 41 products in this category in Q2 2010, while 21 new product registrations and 13 drug master files were submitted during this period.

Earlier this month, the company announced that it has received approval from healthcare sector regulators in the US for the launch of a bioequivalent generic version of Takeda's Prevacid.

It has subsequently introduced its lansoprazole delayed-release capsules in US markets.ADNFCR-8000103-ID-800158490-ADNFCR

Other news stories from 26/10/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd